Biology and Therapeutic Value of Mammalian Aph-1 Homologues
哺乳动物 Aph-1 同源物的生物学和治疗价值
基本信息
- 批准号:6968997
- 负责人:
- 金额:$ 33.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-04-01 至 2010-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Presenilins (PS) form high molecular weight complexes with several other transmembrane proteins, termed NCT, Aph-1 and Pen-2 that are critical for generation of functional gamma-secretase complexes. However, the exact roles of these proteins, particularly for Aph-1 in mammals where two homologous genes exist, in regulation of gamma-secretase complex assembly remain uncertain. Although recent data support the notion that PS, NCT, Aph-1 and Pen-2 comprise the minimal gamma-secretase complex, the precise mechanism whereby
these four components are assembled into the final active complex remain undefined. An interesting question is why there exist two mammalian Aph-1 genes, namely Aph-1a and Aph-1b, encoding three Aph-1 homologues called Aph-1aL, Aph-1aS and Aph-1b. Based on our recent find ings that the phenotype of Aph-1a null embryos resemble but not identical to those of Notch1 null or NCT null embryos, we hypothesize that Aph-1a is the principal mammalian Aph-1 homologue in presenilin-dependent gamma-secretase complexes required for embryonic development and that Aph-1 homologues are developmentally regulated. Thus, we plan in Aim 1 to address these issues by generation and characterization of Aph-1a null, Aph-1b null and
Aph-1a+Aph-1b null mice. Based on our recent findings that the deletion of Aph-1a significantly reduces the levels of mature and immature NCT coupled with the finding that Aph-1 and NCT physically interact, we hypothesize that Aph-1 and NCT are required to regulate the stability of each other to form a stable precomplex for assembling PS and Pen-2. In such a model, we suggest that the three mammalian Aph-1 homologues (Aph-1aL, Aph-1aS and Aph-1b) define a set of six distinct functional gamma-secretase complexes. To test this model, we will generate and characterize a series of mice harboring different combination of Aph-1a and Aph-1b knockout allele and fibroblasts derived from these mice in Aim 2. Since we showed that
Aph-1b null mice are viable and there is reduction in levels of PS and Pen-2 in brains of Aph-1-/- mice, we will test whether deletion of Aph-1b is sufficient to ameliorate Abeta deposition in brains of mutant APP;PS1 mice in Aim 3. Taken together, studies proposed here will address important mechanistic questions regarding physiological roles of mammalian Aph-1 homologues and critically evaluating Aph-1a and Aph-1b as therapeutic targets in efforts to ameliorate Abeta amyloidosis in AD.
早老素(PS)与其他几种跨膜蛋白形成高分子量复合物,称为NCT, Aph-1和Pen-2,这对于生成功能性γ -分泌酶复合物至关重要。然而,这些蛋白,特别是在哺乳动物中存在两个同源基因的Aph-1,在调节γ -分泌酶复合物组装中的确切作用仍然不确定。尽管最近的数据支持PS、NCT、Aph-1和Pen-2组成最小γ -分泌酶复合物的观点,但确切的机制是
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PHILIP C WONG其他文献
PHILIP C WONG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PHILIP C WONG', 18)}}的其他基金
Functional Validation of TDP-43 splicing repression for frontotemporal degeneration
TDP-43 剪接抑制对额颞叶变性的功能验证
- 批准号:
10477324 - 财政年份:2021
- 资助金额:
$ 33.51万 - 项目类别:
Functional Validation of TDP-43 splicing repression for frontotemporal degeneration
TDP-43 剪接抑制对额颞叶变性的功能验证
- 批准号:
10456359 - 财政年份:2021
- 资助金额:
$ 33.51万 - 项目类别:
Functional Validation of TDP-43 splicing repression for frontotemporal degeneration
TDP-43 剪接抑制对额颞叶变性的功能验证
- 批准号:
9926573 - 财政年份:2019
- 资助金额:
$ 33.51万 - 项目类别:
Generation and characterization of a mouse model exhibiting beta-amyloidosis and tauopathy with nuclear depletion of TDP-43
具有 TDP-43 核耗竭的 β-淀粉样变性和 tau 蛋白病小鼠模型的生成和表征
- 批准号:
10618759 - 财政年份:2019
- 资助金额:
$ 33.51万 - 项目类别:
Generation and characterization of a mouse model exhibiting beta-amyloidosis and tauopathy with nuclear depletion of TDP-43
具有 TDP-43 核耗竭的 β-淀粉样变性和 tau 蛋白病小鼠模型的生成和表征
- 批准号:
9893402 - 财政年份:2019
- 资助金额:
$ 33.51万 - 项目类别:
Generation and characterization of a mouse model exhibiting beta-amyloidosis and tauopathy with nuclear depletion of TDP-43
具有 TDP-43 核耗竭的 β-淀粉样变性和 tau 蛋白病小鼠模型的生成和表征
- 批准号:
10687257 - 财政年份:2019
- 资助金额:
$ 33.51万 - 项目类别:
TDP-43 Proteinopathy in ALS-FTD: Mechanism, Target Validation and Biomarker
ALS-FTD 中的 TDP-43 蛋白病:机制、靶标验证和生物标志物
- 批准号:
10583597 - 财政年份:2016
- 资助金额:
$ 33.51万 - 项目类别:
TDP-43 Proteinopathy in ALS-FTD: Mechanism, Target Validation and Biomarker
ALS-FTD 中的 TDP-43 蛋白病:机制、靶标验证和生物标志物
- 批准号:
9078756 - 财政年份:2016
- 资助金额:
$ 33.51万 - 项目类别:
Nicastrin: Physiological Role and Therapeutic Target Validation
尼卡斯特林:生理作用和治疗靶点验证
- 批准号:
6968996 - 财政年份:2005
- 资助金额:
$ 33.51万 - 项目类别:
Alzheimers Disease Mechanism & Experimental Therapeutic
阿尔茨海默病发病机制
- 批准号:
7066534 - 财政年份:2005
- 资助金额:
$ 33.51万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 33.51万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 33.51万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 33.51万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 33.51万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 33.51万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 33.51万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 33.51万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 33.51万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 33.51万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 33.51万 - 项目类别: